Zoetis Inc. announced on September 12, 2025, that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) adopted a positive opinion. This opinion recommends granting marketing authorization for Portela® (relfovetmab), a new monoclonal antibody (mAb) therapy for feline osteoarthritis (OA) pain.
If approved, Portela will be the first long-acting anti-nerve growth factor (NGF) mAb therapy for cats, designed to provide three months of OA pain relief with a single injection. Clinical trials showed Portela was well tolerated and effective, including in cats with kidney disease.
This development represents a significant advancement in feline pain management and expands Zoetis's OA pain franchise in Europe. The European Commission is expected to issue a final decision during the fourth quarter of 2025, with commercial availability anticipated in 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.